ABSTRACT

Introduction  Atrial fibrillation (AF) is the most common cardiac arrhythmia in critically unwell patients. New-onset AF (NOAF) affects 5%–11% of all admissions and up to 46% admitted with septic shock. NOAF is associated with increased morbidity, mortality and healthcare costs. Existing trials into the prevention and management of NOAF suffer from significant heterogeneity making comparisons and inferences limited. Core outcome sets (COS) aim to standardise outcome reporting, reduce inconsistency between trials and reduce outcome reporting bias. We aim to develop an internationally agreed COS for trials of interventions on the management of NOAF during critical illness.

Methods and analysis  Stakeholders including intensive care physicians, cardiologists and patients will be recruited from national and international critical care organisations. COS development will occur in five stages: (1) Outcomes included in trials, recent systematic reviews and surveys of clinician practice and patient focus groups will be extracted. (2) Extracted outcomes will inform a two-stage Delphi process and consensus meeting using Grading of Recommendations Assessment, Development and Evaluation methodology. (3) Outcome measurement instruments (OMIs) will be identified from the literature and a consensus meeting held to agree OMI for core outcomes. (4) Nominal group technique will be used in a final consensus meeting to the COS. (5) The findings of our COS will be published in peer-reviewed journals and implemented in future guidelines and intervention trials.

Ethics and dissemination  The study has been approved by the University of Liverpool ethics committee (Ref: 11256, 21 June 2022), with a formal consent waiver and assumed consent. We will disseminate the finalised COS via national and international critical care organisations and publication in peer-reviewed journals.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ A comprehensive review of the literature, drawing on the most recent systematic reviews and an updated literature search.
⇒ Large representative stakeholder group from the fields of cardiology and intensive care medicine.
⇒ Patient involvement central to the development of Core Outcome Set (COS)-Atrial fibrillation in Critically Unwell (ABACUS) and in accordance with the COS standards of development and COMET initiative recommendations.
⇒ Steering committee comprising experts in the field of atrial fibrillation and COS development.
⇒ A limitation of our study is that high-income countries will likely be over-represented in our stakeholder group; we will attempt to overcome this by embedding the involvement of low-income and middle-income countries, which will increase generalisability of COS-ABACUS.

INTRODUCTION

Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting more than 33 million people worldwide.1 New-onset AF (NOAF) has been defined as AF developing in patients with no medical history of AF. NOAF is the most common cardiac arrhythmia in critically unwell patients.

NOAF affects between 5% and 11% of critically unwell patients admitted to the intensive care unit (ICU) and up to as many as 46% of patients admitted with septic shock.5,6 The development of NOAF in critically unwell patients is associated with haemodynamic instability, higher mortality, increased ICU and hospital length of stay, thromboembolism and the development of chronic permanent AF (PAF).2

Guidelines for the management of AF have been published by the National Institute for Health and Care Excellence,4 the American College of Cardiology/American Heart Association,5 the Canadian Cardiovascular Society,6 Asia Pacific Heart Rhythm Society,7 Japanese Circulation Society8 and the European Society of Cardiology.9 However, they are not directly applicable to patients developing NOAF during critical illness and are largely based on expert consensus.10 In recent years, a number of systematic reviews have...
been published with the aim of determining the optimal treatment strategy for NOAF based on available trial data.\textsuperscript{10–13} Despite the inclusion of over 50 studies across four systematic reviews, interpretation of the evidence is limited due to significant flaws in trial design and heterogeneity between studies. The definition of clinically relevant NOAF varied between trials, and some authors included any atrial tachyarrhythmia as being clinically relevant. Similarly, trials differed significantly in chosen outcome measures and definitions of treatment success. Cardioversion to sinus rhythm and control of heart rate were commonly reported treatment outcomes, however, studies differed significantly in the time period used to define successful cardioversion and the magnitude of heart rate reduction considered to represent a clinically meaningful outcome. Given the morbidity and mortality associated with the development of NOAF, there is an urgent need for adequately powered randomised controlled trials. However, the lack of standardised definitions for NOAF and standardised reproducible outcomes in trials investigating NOAF hinders comparison between trials and development of new management guidelines based on the best evidence.

Core outcome sets (COS) are agreed standard outcomes that should be reported in all clinical trials investigating specific areas of healthcare or specific healthcare conditions.\textsuperscript{14} The use of COS aims to reduce inconsistency between trials and address the issue of outcome reporting bias.\textsuperscript{15,16} COS define the minimum outcomes that should be measured and reported by clinical trials in a particular area of interest (eg, disease, intervention or condition). Previous COS for AF trials have been developed and published elsewhere.\textsuperscript{17–20} However, these COS largely focus on AF developing as part of a chronic progressive arrhythmia spectrum rather than NOAF during acute critical illness. However, patients developing NOAF during critical illness represent a unique patient population with distinct risk factors for the development of AF and different treatment goals compared with patients that develop chronic PAF.\textsuperscript{2} Due to these differences, there is the need for a COS that specifically addresses AF developing in critically unwell patients. Therefore, COS-ATrial fiBrillation in Critically Unwell (ABACUS) aims to achieve international consensus on a minimum dataset of outcomes for inclusion in future trials on AF in critically unwell patients.

The COS will be developed following the methodology of the COMET initiative as set out in the COMET Handbook.\textsuperscript{15} We will develop the COS following the standards of the COS-Standardisation for Development (COS-STAD) and report the COS following the COS-STAD standards for Reporting recommendations.\textsuperscript{14,22} This study was prospectively registered on the COMET Initiative registry of COS (registration number: 2058, Accessible at https://www.comet-initiative.org/Studies/Details/2058).

Scope of COS-ABACUS

A number of COS for AF trials have been published elsewhere.\textsuperscript{20,23} However, AF includes a broad spectrum of clinical manifestations and previous COS have been largely focused on chronic AF or PAF rather than AF as part of critical illness. In COS-ABACUS, we will limit the scope of our COS to adults over 18 years of age who develop NOAF during critical illness. Target interventions will be any pharmacological and non-pharmacological management strategies for the management of AF.

A detailed description of the scope of COS-ABACUS is presented (table 1) as per COS-STAD recommendations.\textsuperscript{14}

Study oversight

A steering committee will provide expert oversight and guide all elements of the development of the COS-ABACUS. Members of the steering committee will be selected based on their expertise in the fields of critical care medicine (IDW, BJ and OC), evidence and data synthesis (RAH), and COS development in intensive care (BB) and cardiology (GYHL). The steering committee will be responsible for management and coordination of each stage of the COS development.

Stakeholders and recruitment

COMET methodology recognises that multiple stakeholders provide differing and expert insights into determining relevant outcomes.\textsuperscript{15} To ensure that the group of stakeholders is as broad and as representative we will recruit members internationally without any geographical or time zone limitations. We will invite stakeholders from several professional groups including:

1. Clinicians primarily practising in intensive care, anaesthetics and cardiology specialties.
2. Nurses and allied health professionals who have a primary role in critical care practice.
3. Researchers and trial investigators that are primary or senior authors of research evaluating interventions for AF in critically unwell patients.
4. Policy makers/funders that have been involved in funding or commissioning research into AF in critically unwell patients.
5. Patients with experience of critical care and those that were treated for AF as part of being critically unwell.

National and international specialty organisations will be approached by email and asked to disseminate information regarding COS-ABACUS to their membership via email lists, organisation social media and organisation

METHODS AND ANALYSIS

This study aims to develop a COS for use in trials on the management of NOAF in critically unwell patients. Critically unwell has been variable defined but for the purposes of COS-ABACUS we will use the definition: ‘a state of ill health with vital organ dysfunction, a high risk of imminent death if care is not provided and the potential for reversibility.’\textsuperscript{21} We will use an international group of patients, researchers and clinicians to reach a consensus on a COS.
newsletters. Details of COS-ABACUS will also be disseminated via the COS-ABACUS social media account. We will target specialty groups related to intensive care medicine, cardiology and critical care research.

Potential participants interested in being involved as a stakeholder will be invited to register their details using an online form. Participants will be invited to stakeholder groups based on expert knowledge and experience from information gathered when registering.

We will approach first and senior authors of trials included in the most recent systematic reviews on the management of NOAF in critically unwell patients.10–12 The editors of specialty journals will be approached for nomination of stakeholder participants based on previously published work in the field of AF in critically unwell patients. In addition, we will conduct a search of Expertscape and SCOPUS databases to identify researchers with an interest in AF in critically unwell patients.24 25

**Patient and public involvement**

Patient involvement is an important and integral aspect in COS development.15 We will approach national patient organisations to ensure that the group of patient stakeholders is as broad as possible and includes patients with an interest in AF or intensive care.26 27 A full list of patient organisations that will be approached is provided in online supplemental table 1. Organisations will be asked to provide information regarding COS-ABACUS to potential stakeholder participants. Potential patient stakeholders will be invited to complete an online form to register their interest in participating in COS-ABACUS. Prior to the Delphi process in stage 2 of COS-ABACUS, a virtual meeting will be held with patient stakeholders during which the aims, methodology involved and process of COS-ABACUS will be discussed. Patient stakeholders will have the opportunity to clarify any concerns or aspects of COS-ABACUS that are not clear. We will involve a patient research ambassador with experience of cardiovascular research to help ensure patient stakeholders voice are fully represented in COS-ABACUS. The patient research ambassador’s role will be to guide patient stakeholders through the COS process and methodology rather than take part as a stakeholder. During this initial meeting, patients will be asked to discuss outcomes that they feel are important and will be asked to anonymously submit outcomes for inclusion in the list of outcomes that will be progressed to stage 1 of COS-ABACUS in preparation for the e-Delphi rounds in stage 2.

**Low-income and middle-income countries**

To ensure as broad and as representative as possible stakeholder group, we aim to ensure that we recruit professional and patient stakeholders from low-income and middle-income countries (LMICs). During review of articles included in stage 1, we will assess relevant publications from LMIC. We will invite first and senior authors to become stakeholders in COS-ABACUS. Our coinvestigator (BB) is lead of the Outcome Measures Working Group at the International Forum for Acute Care Trialists (InFACT) and will be instrumental in increasing

---

**Table 1** Scope of COS-ABACUS presented as per COS-STD recommendations

<table>
<thead>
<tr>
<th>Domain</th>
<th>Standard</th>
<th>COS-ABACUS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Scope</strong></td>
<td>Intensive care</td>
<td>Critical care</td>
</tr>
<tr>
<td><strong>Condition</strong></td>
<td>Atrial fibrillation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. New-onset AF</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Pre-existing AF</td>
<td></td>
</tr>
<tr>
<td><strong>Population</strong></td>
<td>Critically unwell* patients</td>
<td></td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
<td>Any intervention including but not limited to:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. Pharmacological anti-arrhythmic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Non-pharmacological anti-arrhythmic (DCCV)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Anticoagulation</td>
<td></td>
</tr>
<tr>
<td><strong>Stakeholders</strong></td>
<td>Users</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Healthcare professionals</td>
<td>Clinical researchers, trialists, guideline developers, policy makers</td>
</tr>
<tr>
<td></td>
<td>Patients</td>
<td>Patients that develop AF while critically unwell or have pre-existing AF admitted to intensive care, patient representative organisations (eg, Arrhythmia Alliance)</td>
</tr>
<tr>
<td><strong>Consensus process</strong></td>
<td>Initial list of outcomes</td>
<td>Systematic review (Johnston et al)</td>
</tr>
<tr>
<td></td>
<td>review of outcomes in previous systematic review</td>
<td>(O’Bryan et al,13 Drikite et al,10 Wetterslev et al,12 Kanji).</td>
</tr>
<tr>
<td></td>
<td>User surveys (Chean et al,31 Labbe et al,32 Wetterslev et al.33)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>a priori scoring process and consensus definition</td>
<td>Delphi study</td>
</tr>
<tr>
<td></td>
<td>a prior criteria for inclusion/exclusion/adding outcomes</td>
<td>Delphi study</td>
</tr>
<tr>
<td></td>
<td>Avoid ambiguity in language used in the list of outcomes</td>
<td></td>
</tr>
</tbody>
</table>

* A state of ill health with vital organ dysfunction, a high risk of imminent death if care is not provided and the potential for reversibility.21 AF, atrial fibrillation; COS-ABACUS, Core Outcome Set-Atrial fibrillation in Critically Unwell patients; COS-STD, COS-STD andards for Development.
representation from LMIC in COS-ABACUS. InFACT is a network of investigator-led clinical research groups and academic institutions that crucially include representation from the North African Network for Intensive Care Medicine Research, Latin American Critical Care Trials Investigators Network, Latin American Sepsis Institute and the Latin America Intensive Care Network. We will engage with and include InFACT as one of our stakeholder organisations.

We will ensure all material relating to COS-ABACUS is translated into preferred languages for stakeholders who do not speak English as a first language. We aim to conduct COS-ABACUS Delphi process and consensus meetings online to ensure that as many stakeholders can participate as possible and not be limited by geography or time zones. We will work with stakeholders from LMIC and other time zones to ensure they can attend consensus meetings online and if required conduct more than one meeting.

A full list of organisations that will be approached is provided in online supplemental table 1.

**Design of COS-ABACUS**

COS-ABACUS will involve five stages (figure 1).

**Stage 1**
Identifying potentially relevant outcomes through patient stakeholder focus group meetings, an up-to-date systematic review of clinical trials, review of previous systematic reviews and review of clinically relevant outcomes reported in survey responses from clinicians on the management of AF.

**Stage 2**
Determining core outcomes by relevant stakeholder group using an online Delphi process followed by a consensus meeting to finalise core outcome recommendations.

**Stage 3**
Determining measurement instruments for core outcomes through literature review and quality assessment of outcome instruments using the COMET/COSMIN guidelines and COSMIN risk of bias tool. Outcomes will be displayed using a summary of measurement properties table.

**Stage 4**
A final consensus meeting will take place to finalise core outcome instruments selected in stages 2 and 3.

**Stage 5**
COS-ABACUS will be disseminated to all stakeholders’ groups, presented internationally, and published in a peer-reviewed journal.

**Study status**
We aim to commence the updated systematic review included in stage 1 in June 2023. In parallel, we aim to commence recruitment of participants through national and international organisations to COS-ABACUS. COS-ABACUS will run for 48 months with completion of all e-Delphi rounds, consensus meetings and COS-ABACUS finalised by June 2025.

**Stage 1: identifying potential outcomes**

**Systematic literature review**
In stage 1, we will extract outcomes reported in trials included in our recently published systematic review of the management of NOAF in critically unwell adult patients. The full protocol for our systematic review and the final systematic review are published elsewhere.11 28

In addition, we will retrieve outcomes from trials included in two recently published systematic reviews by
We will include the outcome and definitions used. As part similar outcomes will be defined differently between trials. We anticipate that clinically unwell patients. Outcomes will be ranked according to their frequency in published trials. We will retrieve a comprehensive list of outcomes used in previous trials and any quality assessment documented for individual studies.  

To ensure a comprehensive list of outcomes, we will rerun the original search strategy (online supplemental table 2) used in our systematic review. We will extract reported risk of bias assessment for individual studies and any quality assessment documented for individual studies.  

To ensure a comprehensive list of outcomes, we will rerun the original search strategy (online supplemental table 2) used in our systematic review. We will retrieve any articles published after the publication of our systematic review and assess them for inclusion based on our systematic review inclusion and exclusion criteria (online supplemental table 3). Outcomes and outcome definitions used in these trials will be extracted.  

We will generate tables displaying outcomes in rank order with a description of each outcome. We anticipate that studies will differ in the definition of the outcomes used, therefore, we will report each definition and calculate the frequency with which different individual definitions are used. Outcomes will be grouped into domains based on the taxonomy proposed in the COMET handbook. COMET taxonomy includes the following proposed domains: (1) mortality, (2) physiological, (3) infection, (4) pain, (5) quality of life, (6) mental health, (7) psychosocial, (8) functional, (9) compliance, (10) satisfaction, (11) resource use and (12) adverse events.

### User surveys

To provide an insight into the setting and contextual factors that need to be considered in the development of COS-ABACUS, we will review previously published surveys of clinicians practice regarding the management of AF in critically unwell patients. We will aim to identify clinically important outcomes reported by clinicians treating AF in critically unwell patients. We will undertake a quality assessment of any outcome measures using COSMIN checklist methodology.  

The output from stage 1 of COS-ABACUS will be a comprehensive list of outcomes used in previous trials and user surveys from clinicians who manage NOAF in critically unwell patients. Outcomes will be ranked according to their frequency in published trials. We anticipate that similar outcomes will be defined differently between trials. We will include the outcome and definitions used. As part of the e-Delphi and consensus process, we will seek to determine the most used definitions and reach consensus on a definition to be reported as part of COS-ABACUS.

### Stage 2: determining core outcomes

#### Delphi questionnaire

We will undertake an electronic Delphi (e-Delphi) which uses a bespoke online e-management system that is maintained by the COMET initiative. The e-Delphi process will be conducted in accordance with the published recommendations of the COMET initiative.

There are no published recommendations for the optimal number of participants in Delphi rounds. We will attempt to recruit as large a panel size as possible and will aim for at least 5–10 participants from each group of stakeholders (online supplemental table 1).

To limit attrition between e-Delphi rounds, we will send personalised email invitations with a clear study outline with timelines for each e-Delphi round. Each e-Delphi questionnaire will be open for 14 days with an automated email reminder distributed on day 7. We will conduct the second e-Delphi round not more than 4 weeks following completion of round 1.

When participants agree to take part in the e-Delphi process, they will receive study documents that outline the importance of completing all rounds, a summary of time required and plain language summaries. We aim to conduct two e-Delphi rounds, followed by one consensus meeting.

#### Delphi rounds

In round 1 of the e-Delphi process, we will present outcomes extracted from systematic reviews, user surveys and patient focus groups, in stage 1.

To limit presentation bias, we will present outcomes in alphabetical order and provide a plain language definition of each outcome. Participants will be asked to score each outcome on a Likert scale of 1–9 as per the Grading of Recommendations Assessment, Development and Evaluation (GRADE) scale. The GRADE scale categorises scores between 1 and 3 as ‘not that important’, between 4 and 6 as ‘important but not critical’ and scores between 7 and 9 as ‘critically important.’ During round 1, participants will also be asked to provide up to five additional outcomes they feel are important but are missing from the outcomes list. Participants will also have the opportunity to highlight if they would like to modify existing outcomes. New outcomes suggested during rounds 1 and/or 2 will be coded and added into the list of outcomes in alphabetical position. Where uncertainty exists, outcomes will be reviewed by the steering committee.

To help define the composition of the e-Delphi panel, we will collect demographic data for each participant that will be stored on a separate database. Demographic data will include, age, country, years of experience, field of practice, current position and organisation that participants are affiliated with. Patient participants will also be asked if they are an ICU survivor, have been diagnosed...
with NOAF or AF or are affiliated with a particular national or international organisation. Each participant will be provided with a unique identifier to ensure answers and summary reports are anonymised. Completion of the e-Delphi survey will assume implied consent. If participants wish to withdraw their responses, they may do so within 1 week. After 1 week, we will anonymise the responses and disaggregate them from participant identifiable information therefore it will not be possible to responses to be withdrawn for individuals.

A summary report of round 1 of the e-Delphi will be prepared. Outcomes for which 70% or more of participants score 7–9 on the Likert scale and 30% or less score 1–3 on the Likert scale will be retained and presented in round 2. New outcomes suggested in round 1 will be presented and participants will again be asked to score each outcome on a Likert scale of 1–9 as per GRADE scale.36

We anticipate the potential for a significant number of outcomes to be derived during stage one of COS-ABACUS and during round 1 of the e-Delphi. Following publication of the results of e-Delphi round 1, we will hold a feedback session before e-Delphi round 2. Participants will be provided the opportunity to discuss the results of e-Delphi round 1 and will have the opportunity to discuss the outcomes. Patient stakeholders will also be given the opportunity to discuss the results and will be supported by the patient stakeholder ambassador throughout the process. At the end of the feedback session participants will be provided a summary of the discussion prior to taking part in e-Delphi round 2.

During e-Delphi round 2, participants will receive a summary of their own responses, responses by stakeholder group and summary of the feedback session. Participants will be invited to rereview their e-Delphi round 1 rating and provide e-Delphi round 2 ratings for new outcomes.

Responses during e-Delphi round 2 will be analysed as for round 1. At the end of round 2, outcomes considered of ranked 7–9 (critical importance) by 70% of participants will be included in the list of candidate outcomes that will be progressed to the consensus meeting. If there is significant disagreement or significant numbers of new outcomes suggested between e-Delphi rounds, we will consider holding more than two e-Delphi processes.

Consensus meeting
Following the e-Delphi process, the steering committee will discuss the list of outcomes generated and consider whether a consensus meeting is required. If the list of outcomes is small and there is significant consensus between stakeholders, then a consensus meeting may not be necessary. We will, therefore, progress to stage 3 of COS-ABACUS.

Participants who complete the two e-Delphi rounds will be invited to participate in the consensus meeting. We will hold two virtual consensus meetings to allow participants from different time zone localities to participate. The nominal group technique will be used to finalise and develop the COS. In the consensus meeting, we will present the outcomes included following the second e-Delphi round. Outcomes will be presented by stakeholder group and identify any differences between groups. We will ensure that each participant is happy with the definition and understanding of the outcome through group discussion and allowing all participants the opportunity to discuss their views. Following discussion, participants will be asked to vote ‘yes’ or ‘no’ anonymously for inclusion in the final list of outcomes for inclusion in the COS. Outcomes will be classified as ‘critical,’ ‘important but not critical’ and ‘not that important.’ Further rounds of voting my take place until all participants reach consensus. For inclusion in the COS>70% of participants will be required to vote ‘yes’ for inclusion of that outcome.

Stage 3: determining how to measure core outcomes
Stage 3 of COS-ABACUS will be concerned with establishing how to define and measure the core outcomes and outcome measurement instruments (OMI’s) agreed by consensus in stage 2. We will follow the recommendations by COSMIN and COMET for selected OMI’s for outcomes included in COS-ABACUS. The joint initiative by COSMIN and COMET describe the selection of OMI’s involving four main steps:
1. Conceptual considerations, during which the outcome and target population will be defined. Target populations will be defined taking into consideration relevant subgroups such as age and gender. The context of use will also be considered (eg, in hospital, ambulatory or in the community).
2. Finding existing OMI’s in the literature.
3. Quality assessing the OMIs by evaluating the measurement properties and feasibility of the OMIs.
4. Generic recommendation on the selection of OMIs.

Data on OMIs will be extracted by two reviewers (BJ and IDW) from the trials retrieved and included in stage 1 of COS-ABACUS. The SPIRIT 2013 criteria will be used as a framework for extracting data on how outcomes are measures. Outcome data will include (1) the specific name of the variable, (2) analysis metric of the variable (eg, change from baseline, time to event), (3) method of aggregation (eg, median, proportion) and (4) timepoint for the outcome. For patient-reported outcomes, we will use the SPIRIT12-PRO Extension and SPIRIT13-PRO Extension to guide data extraction.

OMIs used in NOAF trials will be identified during stage 1 of COS-ABACUS. We will report the frequency and definition of each OMI. Outcome measures will also be extracted from previous outcome parameters established for ambulatory/chronic AF trials. We will quality assess the evidence of included OMIs as described by COSMIN. Each OMI will be assigned a quality rating of high, moderate, low, very low or unknown as described by COSMIN and in agreement with the GRADE working group.
Stage 4: finalising COS for AF
Participants involved in the previous e-Delphi rounds will be invited to participate in a second consensus meeting. We will hold two consensus meetings to allow participants in different time zones to participate. The aim of the second consensus meeting will be to establish how best to measure the core outcomes and finalise COS-ABACUS. We will rank OMIs for inclusion in the COS based on the findings of stage 3 of COS-ABACUS. We will present the core outcomes, OMIs and quality of the evidence to key stakeholders during virtual consensus meeting. Using nominal group technique, stakeholders will have the opportunity to discuss the OMIs following which they will be asked to vote on OMIs that will be included in COS-ABACUS. We aim to include only one OMI for each core outcome. OMI’s will only be included in the final COS if >70% of participants vote ‘yes’ for their inclusion.

Ethics and dissemination
We obtained ethics approval and formal consent waiver and assumed consent from the University of Liverpool ethics committee (Ref: 11256, 21 June 2022). All answers during the e-Delphi rounds and consensus meetings will be anonymised and only group results will be presented to participants. Agreement to partake in the e-Delphi rounds and consensus meetings will be taken as assumed consent.

A dissemination plan for COS-ABACUS will be agreed by the steering committee. National and international organisations that nominated a stakeholder will be provided with a two-page infographic and copy of the findings agreed COS of COS-ABACUS. COS-ABACUS will be reported in a peer-reviewed journal. Findings will also be presented at national and international conferences in the fields of intensive care medicine and cardiology. We will also present COS-ABACUS via social media and invite stakeholder organisations to disseminate the COS to interested parties.

DISCUSSION
COS-ABACUS will be the first COS designed for use in observational and interventional trials of NOAF in critically unwell patients. Previous AF-related COS have been designed for use in trials investigating chronic AF or PAF. Typically, the goals of treatment and management aims in chronic AF compared with NOAF and this is often reflected in the design and outcomes of research trials. Existing trials investigating NOAF in critically unwell patients have been difficult to interpret given the heterogeneity between what was defined as NOAF, how NOAF was identified and the trials primary and secondary outcomes. It remains unclear how best to manage NOAF, whether a rate control strategy or rhythm control strategy should be employed, what is defined as optimal rate control and whether anticoagulation is required for episodes of NOAF during critical illness. There is an urgent need for adequately powered well designed studies to address these questions. By developing a comprehensive COS, it will be possible to compare studies investigating different management strategies for NOAF.

Strengths and limitations
We believe our study is the first aiming to develop a COS for NOAF in critically unwell patients. Existing COS have focused on AF as part of a chronic arrhythmia spectrum. A limitation of our study may be that there will be considerable overlap in core outcomes generated in our study and those of existing COS. Despite this we believe it is important to highlight common areas of concern to patients and stakeholders between NOAF in critically unwell patient and those with pre-existing AF. We also believe that as patients recover from their critical illness core outcomes important in the long-term management of AF will become more prevalent and important to individual patients and stakeholders. This is important to recognise as long-term outcomes is an area of increasing interest in survivors of critical illness. We aim to include a broad a group of stakeholders as possible. We hope to include LMIC and have factored in translation costs, meetings online and more than one meeting to allow as many stakeholders in different geographical areas as possible to contribute. Despite this we are limited in stage 1 of COS-ABACUS to those studies that are already published in the literature and anticipate that the majority of studies will be English language and lack input from LMIC. While this is an obvious limitation, we hope that COS-ABACUS will highlight the importance of LMIC in future clinical trials investigating the management of NOAF.

Author affiliations
1Institute of Life Course and Medical Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK
2Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK
3Liverpool Reviews & Implementation Group, Institute of Population Health, University of Liverpool, Liverpool, UK
4Queen’s University Belfast Wellcome-Wolfson Institute for Experimental Medicine, Belfast, UK
5Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK

Twitter Brian Johnston @briwbri

Contributors BJ, IDW, RAH and BB conceived COS-ABACUS based upon a previous systematic review. All authors (BJ, RAH, BB, IDW and GHIL contributed to the study design and drafting of the manuscript. BB and RAH provided significant input into COS methodology and will provide expert oversight of all aspect of COS-ABACUS. BJ and IDW will be involved with data extraction, analysis and interpretation for our updated systematic review. All authors have read and approved the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

REFERENCES


## Supplementary Material Table 1

### STAKEHOLDER GROUPS INCLUDED IN COS-ABACUS

<table>
<thead>
<tr>
<th>STAKEHOLDER GROUP</th>
<th>Organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) INTERNATIONAL AND NATIONAL INTENSIVE CARE ORGANISATIONS</td>
<td>Intensive Care Society (UK)</td>
</tr>
<tr>
<td></td>
<td>Faculty of Intensive Care Medicine (UK)</td>
</tr>
<tr>
<td></td>
<td>Royal College of Anaesthetists (UK)</td>
</tr>
<tr>
<td></td>
<td>Intensive Care Society of Ireland (Ireland)</td>
</tr>
<tr>
<td></td>
<td>British Association of Critical Care Nurses</td>
</tr>
<tr>
<td></td>
<td>European Federation of Critical Care Nursing Associations (Europe)</td>
</tr>
<tr>
<td></td>
<td>European Society of Anaesthesiologist’s (Europe)</td>
</tr>
<tr>
<td></td>
<td>European Society of Intensive Care Medicine (Europe)</td>
</tr>
<tr>
<td></td>
<td>Society of Critical Care Medicine (USA)</td>
</tr>
<tr>
<td></td>
<td>Critical Care Societies Collaborative (USA)</td>
</tr>
<tr>
<td></td>
<td>American College of Chest Physicians (USA)</td>
</tr>
<tr>
<td></td>
<td>American Thoracic Society (USA)</td>
</tr>
<tr>
<td></td>
<td>American Association of Critical Care Nurses (USA)</td>
</tr>
<tr>
<td></td>
<td>Canadian Critical Care Society (Canada)</td>
</tr>
<tr>
<td></td>
<td>Australian and New Zealand Intensive Care Research Centre (Australia, New Zealand)</td>
</tr>
<tr>
<td></td>
<td>Australian College of Critical Care Nurses (Australia)</td>
</tr>
<tr>
<td></td>
<td>Australia and New Zealand Intensive Care Society (Australia, New Zealand)</td>
</tr>
<tr>
<td></td>
<td>Chinese Society of Critical Care Medicine (China)</td>
</tr>
<tr>
<td></td>
<td>Japanese Society of Intensive Care Medicine (Japan)</td>
</tr>
<tr>
<td></td>
<td>World Federation of Intensive and Critical Care</td>
</tr>
<tr>
<td>(2) INTERNATIONAL AND NATIONAL CARDIOLOGY ORGANISATIONS</td>
<td>British Heart Foundation (UK)</td>
</tr>
<tr>
<td></td>
<td>British Cardiovascular Society (UK)</td>
</tr>
<tr>
<td></td>
<td>European Society of Cardiology (Europe)</td>
</tr>
<tr>
<td></td>
<td>Canadian Cardiovascular Society (Canada)</td>
</tr>
<tr>
<td></td>
<td>American College of Cardiology (USA)</td>
</tr>
<tr>
<td></td>
<td>American Heart Association (USA)</td>
</tr>
<tr>
<td></td>
<td>Cardiology Society of Australia and New Zealand (Australia and New Zealand)</td>
</tr>
<tr>
<td></td>
<td>Chinese Society of Cardiology (China)</td>
</tr>
<tr>
<td></td>
<td>Japanese Circulation Society (Japan)</td>
</tr>
<tr>
<td></td>
<td>Korean Society of Cardiology (Korea)</td>
</tr>
<tr>
<td></td>
<td>South African Heart Association (South Africa)</td>
</tr>
<tr>
<td>(3) PATIENT REPRESENTATIVE GROUPS</td>
<td>Arrhythmia Alliance</td>
</tr>
<tr>
<td></td>
<td>AF Association</td>
</tr>
<tr>
<td></td>
<td>ICUSteps</td>
</tr>
<tr>
<td></td>
<td>COMET PoPPIE working group</td>
</tr>
<tr>
<td>(4) ACADEMIC AND</td>
<td>National Association of Academic Anaesthetists</td>
</tr>
</tbody>
</table>
| RESEARCH / MIXED STAKEHOLDER GROUP | Intensive Care National Audit and Research Centre  
| National Institute for Health and Care Research  
| United Kingdom Critical Care Research Group (UK)  
| China Critical Care Clinical Trial Group (China)  
| Canadian Critical Care Trials Group (Canada) |
| (5) JOURNAL EDITORS | Journal of the American College of Cardiology  
| Circulation  
| Journal of the American Heart Association  
| JAMA Cardiology  
| Circulation Research  
| European Heart Journal  
| International Journal of Cardiology  
| Nature Reviews Cardiology  
| Heart Rhythm  
| American Heart Journal  
| American Journal of Respiratory and Critical Care Medicine  
| Intensive Care Medicine  
| Critical Care Medicine  
| Critical Care  
| Chest  
| Annals of Intensive Care  
| European Heart Journal: Acute Cardiovascular Care  
| Journal of Intensive Care  
| Journal of Intensive Care Medicine  
| Journal of Critical Care |
| (6) LMIC SPECIFIC STAKEHOLDER GROUPS | Outcome Measures Working Group of International Forum for Acute Care Trialists (InFACT)  
| North African Network for Intensive Care Medicine Research (NANICM Research)  
| Latin American Critical Care Trials Investigators Network (LACCTIN)  
| Latin American Sepsis Institute (LASI)  
| Latin American Intensive Care Network (LIVEN)  
| Jaffna University, Sri Lanka |
Supplementary material Table 2.

Medline and Embase search strategies that will be used in systematic review.

<table>
<thead>
<tr>
<th>Databases</th>
<th>Date searched</th>
<th>No. retrieved</th>
</tr>
</thead>
<tbody>
<tr>
<td>MEDLINE (Ovid), Epub ahead of print and MEDLINE In-Process (Ovid)</td>
<td>11/12/2018</td>
<td>662</td>
</tr>
<tr>
<td>EMBASE (Ovid)</td>
<td>11/12/2018</td>
<td>1298</td>
</tr>
</tbody>
</table>

Search strategies

Database: Medline

Strategy used:

1. Atrial Fibrillation/ 48328
2. (Atrial* adj2 (Fibrillat* or flutter)).tw. 63328
3. AF.tw. 34240
4. (tachycardia or tachyarrhythmia or arrhythmia or supraventricular).tw. 87656
5. 1 or 2 or 3 or 4 160116
6. ((new* or recent*) adj1 diagno*).tw. 63298
7. (onset* or new*).tw. 304895
8. 6 or 7 305302
9. Critical Care/ 47996
10. Critical Illness/ 24797
11. ((critical* or intensiv*) adj4 (care or ill*)).tw. 176778
12. ((critical* or intensiv*) adj4 (care or ill* or unwell*)).tw. 176812
13. 9 or 10 or 11 or 12 198998
14. 5 and 8 and 13 662

Database: Embase

Strategy used:
<table>
<thead>
<tr>
<th></th>
<th>Term</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Atrial Fibrillation/</td>
<td>41928</td>
</tr>
<tr>
<td>2</td>
<td>(Atrial* adj2 (Fibrillat* or flutter)).tw.</td>
<td>109441</td>
</tr>
<tr>
<td>3</td>
<td>AF.tw.</td>
<td>65045</td>
</tr>
<tr>
<td>4</td>
<td>(tachycardia or tachyarrhythmia or arrhythmia or supraventricular).tw.</td>
<td>121780</td>
</tr>
<tr>
<td>5</td>
<td>1 or 2 or 3 or 4</td>
<td>240819</td>
</tr>
<tr>
<td>6</td>
<td>((new* or recent*) adj1 diagno*).tw.</td>
<td>107104</td>
</tr>
<tr>
<td>7</td>
<td>(onset* or new*).tw.</td>
<td>3689424</td>
</tr>
<tr>
<td>8</td>
<td>6 or 7</td>
<td>3695973</td>
</tr>
<tr>
<td>9</td>
<td>Critical Care/</td>
<td>88512</td>
</tr>
<tr>
<td>10</td>
<td>Critical Illness/</td>
<td>26890</td>
</tr>
<tr>
<td>11</td>
<td>((critical* or intensiv*) adj4 (care or ill*)).tw.</td>
<td>254629</td>
</tr>
<tr>
<td>12</td>
<td>((critical* or intensiv*) adj4 (care or ill* or unwell*)).tw.</td>
<td>254703</td>
</tr>
<tr>
<td>13</td>
<td>9 or 10 or 11 or 12</td>
<td>295857</td>
</tr>
<tr>
<td>14</td>
<td>5 and 8 and 13</td>
<td>1399</td>
</tr>
<tr>
<td>15</td>
<td>limit 14 to medline</td>
<td>91</td>
</tr>
<tr>
<td>16</td>
<td>14 not 15</td>
<td>1308</td>
</tr>
<tr>
<td>17</td>
<td>remove duplicates from 16</td>
<td>1298</td>
</tr>
</tbody>
</table>
Table 3. Eligibility criteria for systematic review.

<table>
<thead>
<tr>
<th>Inclusion criteria (if all of the following met)</th>
<th>Exclusion criteria (if any of the following met)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Population comprised adults admitted to a critical care setting (ICU, HDU, A+E, AMU) who have developed or develop NOAF including paroxysmal AF (rhythm classification by continuous ECG monitoring or 12 lead ECG)</td>
<td>1. Population includes patients younger than 18 years, pregnant women, patients with known AF or a history of previous episodes of AF, patients who have undergone or are scheduled to undergo cardiac surgery, permanent pacemaker insertion or surgical ablation, or patients post cardiac/thoracic surgery</td>
</tr>
<tr>
<td>2. Intervention was any anti-arrhythmic or rate control medication (including but not limited to beta antagonists, calcium channel antagonists, Digoxin, Amiodarone, Magnesium), DCCV, or any combination of these interventions</td>
<td>2. Case reports and studies with no original data presented (e.g., design/protocol paper, [systematic] review, meta-analysis, commentary/editorial)</td>
</tr>
<tr>
<td>3. Comparator was any of the interventions above, placebo, standard care or no comparator</td>
<td>3. Insufficient information (e.g., study only available as a conference proceeding/abstract)</td>
</tr>
<tr>
<td>4. Primary outcome measures included achievement of heart rhythm control/cardioversion to sinus rhythm or achievement of heart rate control (defined as heart rate less than 110 bpm); Secondary outcomes included: a. development of permanent atrial fibrillation, b. development of recurrent paroxysmal atrial fibrillation that terminates within 48 h as defined by the ESC, c. any thromboembolic events (such as stroke pulmonary embolism, deep vein thrombosis, left atrial thrombus) during critical care admission, d. development of major bleeding events after administration of therapeutic anticoagulation as recommended in NICE guidelines; e. any complication documented secondary to the intervention, f. last reported mortality, g. ICU mortality, h. length of stay in critical care and length of hospital stay</td>
<td>5. RCTs, quasi-RCTs and prospective or retrospective observational studies published in peer-reviewed journals</td>
</tr>
</tbody>
</table>

NOAF defined as AF occurring during admission in a patient with no history of chronic AF. We also included studies of new-onset supraventricular arrhythmias (SVAs) where AF was the dominant arrhythmias.

AF=atrial fibrillation; ECG=electrocardiogram; ESC=European Society of Cardiology; HDU=high dependency unit; ICU=intensive care unit; A+E=emergency department; AMU=acute medical unit; NICE=National Institute of Health and Care Excellence; NOAF=new onset atrial fibrillation; RCT=randomised controlled trial; DCCV=direct current cardioversion